Etiopathogeny of Multiple Myeloma Associated With Breast Cancer: Case Reports
,
Abstract
The association between multiple myeloma and solid cancers is rarely described in the literature. Some authors report that multiple myeloma increases the risk of developing some cancers such as breast cancer. We report three cases of multiple myeloma and breast cancer metachronous in order to study the etiopathogenesis of this association. Such a big spectrum of these studies should be done to understand whether there is a relation between causes of these two diseases or the risk factors behind this rare association. Our objective is to be able to define patients with high and low risk of developing secondary cancer in order to adapt the therapies and propose possibly screening for colon and breast cancers every two years for patients with high-risk multiple myeloma.
1. Portier M1, Molès JP, Mazars GR, Jeanteur P, Bataille R, Klein B, Theillet C : p53 and RAS gene mutations in multiple myeloma. Oncogene. 1992 Dec;7(12):2539-43.
2. Jorge J. Castillo &Morie A. Gertz (2016): Secondarymalignancies in patientswith multiple myeloma, Waldenströmmacroglobulinemia and monoclonal gammopathy ofundeterminedsignificance, Leukemia&Lymphoma, DOI: 10.1080/10428194.2016.1217527.
3. Jonsdottir G, Lund SH, Bjorkholm M, et al. Survival inmultiple myeloma patients whodevelop secondmalignancies: a population-basedcohortstudy.Haematologica. 2016; 101:e145–e148.
4. P. Collins, S. Vijgen, B. De Prijck, N. Blétard, Y. Beguin, P. Delvenne. Chimiothérapie, immunodépression et cancers secondaires : rapport d’un cas clinique. Rev Med Liège 2013; 68: 7-8: 418-422.
5. Palumbo A, Hajek R, Delforge M, et al. — Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med, 2012, 366, 1759-1769.
6. The myeloma beacon. — http://www.myelomabeacon. com - Consultation du 1erseptembre 2012.
7. McCarthy PL, Owzar K, Hofmeister CC, et al. — Lena¬lidomide after stem-cell transplantation for multiple myeloma. N Engl J Med, 2012, 366, 1770-1781.
8. Attal M, Lauwers-Cances V, Marit G, et al. Lenali¬domide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med, 2012, 366, 1782- 1791.
9. Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes following multiple myeloma and its precur¬sor disease (MGUS). Blood, 2011, 118, 4086-4092.
10. ANeri, L Baldini, D Trecca, L Cro, E Polli and AT Maiolo. P53 Gene Mutations in Multiple Myeloma Are Associated With Advanced Forms of Malignancy.Blood .1993 81: 128-135
11. Hollstein M, Sidransky D, Vogelstein B, Harris CC: P53 mutations in human cancers. Science 253:49, 1991.
12. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer: A review. Int J Cancer 57:1, 1994.
13. Thorlacius S, Borresen AL, Eyfjord JE: Somatic p53 mutations in human breast carcinomas in an Icelandic population: A prognostic factor. Cancer Res 53:1637, 1993.
14. Portier M, Moles J-P, Mazars G-R, Jeanteur P, Bataille R, Klein B, Theillet C: p53 and RAS gene mutations in multiple myeloma.Oncogene 7:2539, 1992.
15. Owen RG, Davis SAA, Randerson J, Rawstron AC, Davies F, Child JA, Jack AS, Morgan GJ: p53 gene mutations in multiple myeloma. J ClinPathol: MolPathol 50:18, 1997.
16. LynchHT, Ferrara, BarlogieBet al. Familial myeloma. N Engl J Med 2008; 359: 152–157.
17. Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med. 2011; 365(23):2241-2242.
.
2. Jorge J. Castillo &Morie A. Gertz (2016): Secondarymalignancies in patientswith multiple myeloma, Waldenströmmacroglobulinemia and monoclonal gammopathy ofundeterminedsignificance, Leukemia&Lymphoma, DOI: 10.1080/10428194.2016.1217527.
3. Jonsdottir G, Lund SH, Bjorkholm M, et al. Survival inmultiple myeloma patients whodevelop secondmalignancies: a population-basedcohortstudy.Haematologica. 2016; 101:e145–e148.
4. P. Collins, S. Vijgen, B. De Prijck, N. Blétard, Y. Beguin, P. Delvenne. Chimiothérapie, immunodépression et cancers secondaires : rapport d’un cas clinique. Rev Med Liège 2013; 68: 7-8: 418-422.
5. Palumbo A, Hajek R, Delforge M, et al. — Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med, 2012, 366, 1759-1769.
6. The myeloma beacon. — http://www.myelomabeacon. com - Consultation du 1erseptembre 2012.
7. McCarthy PL, Owzar K, Hofmeister CC, et al. — Lena¬lidomide after stem-cell transplantation for multiple myeloma. N Engl J Med, 2012, 366, 1770-1781.
8. Attal M, Lauwers-Cances V, Marit G, et al. Lenali¬domide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med, 2012, 366, 1782- 1791.
9. Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes following multiple myeloma and its precur¬sor disease (MGUS). Blood, 2011, 118, 4086-4092.
10. ANeri, L Baldini, D Trecca, L Cro, E Polli and AT Maiolo. P53 Gene Mutations in Multiple Myeloma Are Associated With Advanced Forms of Malignancy.Blood .1993 81: 128-135
11. Hollstein M, Sidransky D, Vogelstein B, Harris CC: P53 mutations in human cancers. Science 253:49, 1991.
12. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer: A review. Int J Cancer 57:1, 1994.
13. Thorlacius S, Borresen AL, Eyfjord JE: Somatic p53 mutations in human breast carcinomas in an Icelandic population: A prognostic factor. Cancer Res 53:1637, 1993.
14. Portier M, Moles J-P, Mazars G-R, Jeanteur P, Bataille R, Klein B, Theillet C: p53 and RAS gene mutations in multiple myeloma.Oncogene 7:2539, 1992.
15. Owen RG, Davis SAA, Randerson J, Rawstron AC, Davies F, Child JA, Jack AS, Morgan GJ: p53 gene mutations in multiple myeloma. J ClinPathol: MolPathol 50:18, 1997.
16. LynchHT, Ferrara, BarlogieBet al. Familial myeloma. N Engl J Med 2008; 359: 152–157.
17. Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med. 2011; 365(23):2241-2242.
.
| Files | ||
| Issue | Vol 61 No 2 (2023) | |
| Section | Case Report(s) | |
| DOI | https://doi.org/10.18502/acta.v61i2.12559 | |
| Keywords | ||
| Multiple myeloma Breast cancer Association Etiopathogeny | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Khemiri S, Feki J, Toumi N, Khanfir A. Etiopathogeny of Multiple Myeloma Associated With Breast Cancer: Case Reports. Acta Med Iran. 2023;61(2):122-125.
